Everything you care about in one place

Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.

Get Feeder


Press releases

Get the latest updates from Press releases directly as they happen.

Follow now 457 followers

Latest posts

Last updated 3 days ago

Statement: Zantac (ranitidine) litigation – Kasza case

3 days ago

GSK welcomes the plaintiff's voluntary dismissal of Zantac case (Kasza) in Illinois.

Statement: Zantac (ranitidine) litigation – GSK starts process for appeal of recent Delaware Daubert decision

3 days ago

GSK confirms that the Company has taken the first step to seek...

GSK accelerates oligonucleotide platform and pipeline medicines with acquisition of Elsie Biotechnologies

8 days ago

Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with...

Blenrep combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma

12 days ago

DREAMM-8 phase III trial showed statistically significant and clinically meaningful improvement.

Statement: Zantac (ranitidine) litigation – Delaware State Court Daubert Ruling

13 days ago

GSK disagrees with ruling by the Delaware State Court and will immediately...

Statement: Zantac (ranitidine) litigation - Valadez and Williams cases

22 days ago

Jury in Valadez case in Illinois state court finds GSK not liable...

New data at ASCO showcases the transformational potential of GSK's oncology portfolio

22 days ago

Pivotal data will be shared from the DREAMM-8 and DREAMM-7 phase III...

GSK announces positive results from phase III severe asthma trials of depemokimab

24 days ago

Primary endpoints met in SWIFT-1 and SWIFT-2 trials with statistically significant reduction...

GSK to become a founding partner of Fleming Initiative to fight antimicrobial resistance (AMR)

29 days ago

GSK pledges to support the Fleming Initiative - an innovative and collaborative...

GSK makes a strong start to 2024 with improving outlook for the year

about 1 month ago

Q1 2024 performance highlights